Burgdorf – Ypsomed has been the exclusive distributor for the mylife OmniPod® patch pump outside the USA since 2010. During this period, Ypsomed established therapy with the innovative insulin pump in Europe, gaining market shares of up to 20% in part. The distribution agreement with Insulet Corp. will end as per 30 June 2018. The parties could not agree on extending the contract as the price demanded by Insulet Corp. would have made continued economic viability impossible. Ypsomed is well set for the future and will introduce its own tubeless mylife YpsoPod® insulin pump in the mid-term.

Ypsomed expands to more countries with its YpsoPump insulin pump

Press Releases Ypsomed Group

Burgdorf – Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.

Press Releases Ypsomed Group

Burgdorf – Ypsomed has collaborated with Biocon, an emerging global biopharmaceutical company headquartered in India, to customise its reusable YpsoPen for use with Biocon’s insulin cartridges. This customised reusable pen will be marketed by Biocon as INSUPen Pro™ in Malaysia.